Unveiling the Potential of Biosimilars:
Past Achievements and Future Prospects

Date & Time: Mar 21, 2024 10 AM EST / 3 PM CET

Description:

The field of biosimilars, which seeks to offer cost-effective alternatives to biologic drugs, has garnered significant attention in recent years. This report aims to provide an in-depth analysis of the biosimilar industry, tracing its evolution, examining its current market status over the past three years, and exploring future opportunities. 

Omnitrope's launch in 2006 was a pivotal moment for biosimilars, introducing them as viable options in healthcare. Initial regulatory hurdles were substantial, as biosimilar guidelines were nascent. The industry saw a turning point with the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) establishing a comprehensive approval pathway, which has since facilitated the entry of numerous biosimilars into the market.

This report details the biosimilars approved up to the present, segmented by therapeutic application—such as treatments for growth hormone deficiency, anaemia, and autoimmune diseases. We highlight the first biosimilar moieties launched between 2021 and 2023, including their regulatory approvals and market impact on their reference drugs. The current regulatory environment and market dynamics for biosimilars are evaluated to understand their position in the healthcare landscape. We will analyze the upcoming biosimilars anticipated for launch in the upcoming years and their respective focused indications. 

The webinar offers a comprehensive analysis of the biosimilar landscape, from its inception to its future prospects. The increasing focus on research and development, combined with regulatory advancements, underscores the significant role biosimilars will play in enhancing patient access to affordable, effective treatments. 

Speakers

Samreen Shaikh

Lead Pharma Solutions·Springer Nature

Samreen Shaikh is the Lead Pharma Solutions at Springer Nature, Pune, with over 15 years of experience in the field, including 6 years in Pharma Solutions at Springer Nature. She joined Springer Nature in 2018 and has been instrumental in handling new initiatives and is a subject matter expert in the AdisInsight team. Additionally, Ms. Shaikh has an impressive academic background, with 9 years of experience as an Assistant Professor at Pune University, India. She holds an M.S. (Pharm) degree specializing in Medicinal Chemistry from National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India

Daniela Ranzani

AdisInsight Senior Product Manager·Springer Nature

Daniela Ranzani has worked as AdisInsight Product Manager with Springer Nature since 2012 and, prior to this role, held a Licensing Manager role for the Pharma and Hospitals & Health markets in Italy, UK and Northern Europe. After an MSc in Medical Biotechnology, She started her career in the regulatory field with experiences both at the European Medicines Agency and the MHRA in London, and as Client Services Account Executive for Wolters Kluwer in both London and Milan, with responsibility for customer relationship, training & support and client retention, which are still very much part of my current role alongside product development.